Northwest Biotherapeutics, Inc.
NWBO
$0.17
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.17M | 1.50M | 1.38M | 937.00K | 1.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.17M | 1.50M | 1.38M | 937.00K | 1.09M |
| Cost of Revenue | 23.57M | 25.29M | 28.79M | 33.75M | 34.43M |
| Gross Profit | -21.39M | -23.80M | -27.41M | -32.82M | -33.34M |
| SG&A Expenses | 28.94M | 29.71M | 32.51M | 32.09M | 32.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.50M | 55.00M | 61.29M | 65.85M | 66.48M |
| Operating Income | -50.33M | -53.50M | -59.91M | -64.91M | -65.39M |
| Income Before Tax | -38.27M | -44.43M | -60.70M | -89.77M | -82.32M |
| Income Tax Expenses | -537.00K | -537.00K | -537.00K | -- | -- |
| Earnings from Continuing Operations | -37.73 | -43.89 | -60.16 | -89.77 | -82.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.73M | -43.89M | -60.16M | -89.77M | -82.32M |
| EBIT | -50.33M | -53.50M | -59.91M | -64.91M | -65.39M |
| EBITDA | -47.61M | -51.10M | -57.85M | -63.14M | -63.62M |
| EPS Basic | -0.03 | -0.03 | -0.04 | -0.07 | -0.06 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.03 |
| EPS Diluted | -0.03 | -0.03 | -0.05 | -0.07 | -0.07 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 6.25B | 6.05B | 5.83B | 5.60B | 5.36B |
| Average Diluted Shares Outstanding | 6.25B | 6.05B | 5.83B | 5.60B | 5.36B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |